Trial Profile
A Prospective, Open-Label, Double-Arm, Crossover, Single-Center Pilot Study to Evaluate the Addition of Raltegravir to Established Suppressive Antiretroviral Therapy While Monitoring Changes in Markers of Immune Activation Among HIV-1 Infected Individuals Without Adequate Immune Restoration
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Raltegravir (Primary) ; Antiretrovirals
- Indications HIV infections
- Focus Pharmacodynamics
- 28 Oct 2016 Status changed from active, no longer recruiting to discontinued.
- 02 Jun 2015 Planned End Date changed from 1 Jan 2015 to 1 Oct 2015, according to to ClinicalTrials.gov record.
- 09 Dec 2014 Planned End Date changed from 1 Jun 2012 to 1 Jan 2015 as reported by ClinicalTrials.gov.